Skip to main content

Table 3 Mean Percentage ± SD Cytotoxicity during Treatment against the SKOV3 Ovarian Tumor Cell Line

From: Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin

 

Course 1

MO Treatment

Day -8

Day -4

Day 1

Day 9

3 Months*

None

0.8 ± 1.9 (8)

2.4 ± 3.6 (8)

1.3 ± 1.4(6)

2.8 ± 3.4 (7)

1.9 ± 0.9(3)

2B6 antibody

1.0 ± 2.3 (6)

2.3 ± 2.7 (6)

4.1 ± 3.2(4)

4.6 ± 3.0 (5)

4.6 ± 2.3(3)

trastuzumab

2.5 ± 3.1 (8)

3.7 ± 3.1 (8)

5.8 ± 4.7(8)

4.7 ± 5.4 (7)

4.3 ± 3.0(3)

trastuzumab + 2B6 a/b

4.1 ± 4.4 (6)

5.2 ± 3.3 (6)

10.8 ± 8.5(6)

7.6 ± 4.3 (6)

8.7 ± 5.0(3)

  1. *Three months after first chemoimmunotherapy course was begun. (n) = number of patients tested at each time period. P > .05 for day -8 vs each of the other categories (day -4, day 1, day 9, or 3 months).